All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Nucana Ltd. is poised to start phase III development of its lead product Acelarin after reporting what it claimed as "groundbreaking" phase I/II data for the modified version of gemcitabine at the American Society of Clinical Oncology meeting in Chicago on Saturday.